Meloxicam effect on coagulogram parameters in patients with back pain after COVID-19

Meloxicam effect on coagulogram parameters in patients with back pain after COVID-19

M.V. Putilina¹, N.I. Shabalina², D.V. Grishin³, O.V. Kurushina⁴

¹Pirogov Russian National Research Medical University, Moscow

²Central Clinical Hospital RZD-Medicine, Moscow

³City Clinical Hospital No. 15, Moscow

⁴Volgograd State Medical University, Volgograd

Background: musculoskeletal symptoms commonly develop or worsen in patients who had COVID-19. The occurrence of musculoskeletal pain after infection can probably be explained by the direct primary viral attack to the muscles and peripheral nerves, and secondary hypoxia, which enhances the processes of hypercoagulation and inflammation, as well as microcirculatory disorders with the microthrombosis development.

Aim: to study the meloxicam effect on coagulogram parameters in patients with back pain after COVID-19.

Patients and Methods: a retrospective study included 50 patients aged 35 to 50 years with a diagnosis of dorsopathy (lower back pain), who had suffered COVID-19 within 40 to 90 days before inclusion in the study. Pain syndrome therapy included the prescription of meloxicam, a solution for intramuscular administration of 10 mg/mL (intramuscularly, 1.5 ml once a day for 10 days). All patients were examined during the first visit (Visit 1) and 14 days after therapy (Visit 2). At each visit, the following indicators were assessed: neurological status and the pain severity on a visual analog scale (VAS). Laboratory tests were performed a day after Visits 1 and 2: complete blood count with platelet count, levels of inflammatory markers and coagulogram indicators.

Results: 10 days after therapy with meloxicam, a statistically significant reduction of pain syndrome according to VAS (p<0.001) was registered. During the treatment, there was a significant decrease in the ESR and C-reactive protein levels, normalization of platelet levels, as well as there was no effect on activated partial thromboplastin time (APTT), thromboplastin time (TT), prothrombin time in a statistically significant decrease in the D-dimer level (p<0.006). There were no adverse events during the meloxicam use.

Conclusion: meloxicam had no effect on coagulogram parameters in patients with back pain after COVID-19.

Keywords: meloxicam, COVID-19, dorsopathy, back pain, inflammatory markers, coagulogram, musculoskeletal symptoms.

For citation: Putilina M.V., Shabalina N.I., Grishin D.V., Kurushina O.V. Meloxicam effect on coagulogram parameters in patients with back pain after COVID-19. RMJ. 2022;4:11–14.